ImmuCell Corporation

5.28-0.1800-3.30%Vol 5511Y Perf -8.65%
Sep 22nd, 2020 14:50 DELAYED
BID5.51 ASK5.64
Open5.33 Previous Close5.46
Pre-Market- After-Market-
 - -%  - -%
Target Price
14.00 
Analyst Rating
— — 0.00
Potential %
165.15 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★+     55.93
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★★★     58.22
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap38.08M 
Earnings Rating
Neutral
Price Range Ratio 52W %
35.67 
Earnings Date
9th Nov 2020

Today's Price Range

5.285.33

52W Range

3.708.13

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-0.19%
1 Month
-5.38%
3 Months
16.56%
6 Months
14.78%
1 Year
-8.65%
3 Years
-15.52%
5 Years
-14.42%
10 Years
72.55%

TickerPriceChg.Chg.%
ICCC5.28-0.1800-3.30
AAPL111.811.73001.57
GOOG1 465.4634.30002.40
MSFT207.424.88002.41
XOM35.53-0.9000-2.47
WFC23.65-0.3900-1.62
JNJ144.21-0.8900-0.61
FB254.756.60002.66
GE6.25-0.1000-1.57
JPM94.27-1.0400-1.09
Financial StrengthValueIndustryS&P 500US Markets
3.90
4.80
0.26
0.39
-1.70
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
47.00
-7.50
8.20
-0.50
-11.75
RevenueValueIndustryS&P 500US Markets
14.48M
2.01
12.34
7.85
Earnings HistoryEstimateReportedSurprise %
Q02 2020--0.11-
Q02 2016-0.00-
Q01 2016-0.11-
Q04 2015-0.09-
Q03 2015-0.11-
Q02 2015-0.03-
Q01 2015-0.15-
Q04 2014-0.04-
Earnings Per EndEstimateRevision %Trend
12/2020 FY-0.24--
12/2021 FY-0.11--
----
----
Next Report Date9th Nov 2020
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume551
Shares Outstanding7.21M
Trades Count20
Dollar Volume4.06K
Avg. Volume45.04K
Avg. Weekly Volume5.80K
Avg. Monthly Volume8.48K
Avg. Quarterly Volume16.91K

ImmuCell Corporation (NASDAQ: ICCC) stock closed at 5.28 per share at the end of the most recent trading day (a -3.3% change compared to the prior day closing price) with a volume of 551.0000 shares and market capitalization of 38.08M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 52 people. ImmuCell Corporation CEO is Micheal F. Brigham.

The one-year performance of ImmuCell Corporation stock is -8.65%, while year-to-date (YTD) performance is 2.52%. ICCC stock has a five-year performance of -14.42%. Its 52-week range is between 3.7 and 8.13, which gives ICCC stock a 52-week price range ratio of 35.67%

ImmuCell Corporation currently has a PE ratio of -, a price-to-book (PB) ratio of 1.44, a price-to-sale (PS) ratio of 2.72, a price to cashflow ratio of 23.80, a PEG ratio of 2.32, a ROA of -4.25%, a ROC of -2.98% and a ROE of -5.87%. The company’s profit margin is -11.75%, its EBITDA margin is 8.20%, and its revenue ttm is $14.48 Million , which makes it $2.01 revenue per share.

Of the last four earnings reports from ImmuCell Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. ImmuCell Corporation’s next earnings report date is 09th Nov 2020.

The consensus rating of Wall Street analysts for ImmuCell Corporation is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for ImmuCell Corporation stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ImmuCell Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ImmuCell Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.63, ATR14 : 0.25, CCI20 : -19.72, Chaikin Money Flow : -0.07, MACD : -0.03, Money Flow Index : 64.93, ROC : -0.75, RSI : 47.14, STOCH (14,3) : 31.48, STOCH RSI : 0.13, UO : 42.00, Williams %R : -68.52), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ImmuCell Corporation in the last 12-months were: David S. Cunningham (Buy at a value of $8 000), David S. Tomsche (Buy at a value of $45 235)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies.

CEO: Micheal F. Brigham

Teplephone: +1 207 878-2770

Address: 56 Evergreen Drive, Portland 04103, ME, USA

Number of employees: 52

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

47%53%

Bearish Bullish

70%30%

News

Stocktwits